Table III.

Effect of wild-type genotype by treatment regimen

Gene	SNP	Chemoradiation (N = 243)			Chemotherapy (N = 355)			Group
		Effect on survival	HRa	P	Effect on survival	HRa	P
BMP2	rs235753	Favorable	0.54 (0.33–0.88)	0.01	Unfavorable	1.20(1.01-1.45)	0.038	Group 1
TGFBR1	rs868	Favorable	0.63 (0.43–0.92)	0.02	Unfavorable	1.10(0.66–1.85)	0.85
ACVR1B	rs877869	Favorable	0.69 (0.53–0.91)	0.008	Unfavorable	1.12(0.87–1.43)	0.61
SMAD3	rs11071933	Favorable	0.68 (0.47–1.00)	0.05	Unfavorable	1.03(0.79–1.35)	0.79
SMAD4	rs948588	Favorable	0.96 (0.56–1.64)	0.88	Unfavorable	1.47(1.01–2.13)	0.04
SMAD6	rs3934908	Favorable	0.90 (0.60–1.33)	0.59	Unfavorable	1.35(1.05–1.72)	0.02
SMAD6	rs4776318	Favorable	0.73 (0.56–0.93)	0.01	Unfavorable	1.10(0.81–1.52)	0.57
SMAD6	rs4075546	Favorable	0.68 (0.53–0.88)	0.003	Unfavorable	1.11(0.76–1.61)	0.60
TGFB1	rs4803455	Unfavorable	1.35 (0.90–2.04)	0.14	Favorable	0.67(0.51–0.89)	0.006	Group 2
BMP2	rs235757	Unfavorable	1.47 (1.10–1.96)	0.01	Favorable	0.83(0.58–1.19)	0.40
TGFBR1	rs928180	Unfavorable	1.72 (1.05–2.78)	0.03	Favorable	0.95(0.69–1.32)	0.78
BMP2	rs173107	Unfavorable	1.49 (1.11–2.00)	0.007	Favorable	0.92(0.63–1.33)	0.81
SMAD3	rs9972423	Unfavorable	1.23 (0.94–1.61)	0.13	Favorable	0.81(0.67–0.98)	0.03
SMAD3	rs12915039	Unfavorable	2.50 (1.01–6.25)	0.05	Favorable	0.80(0.47–1.35)	0.40
SMAD4	rs1787111	Unfavorable	1.39 (0.63–3.03)	0.41	Favorable	0.51(0.32–0.81)	0.006
SMAD8	rs9531986	Unfavorable	2.00 (0.83–2.27)	0.21	Favorable	0.76(0.58–0.99)	0.04
TGFB1	rs11466345	Favorable	0.61 (0.38–0.99)	0.04	Favorable	0.85(0.62–1.16)	0.31	Group 3
BMP1	rs4076873	Favorable	0.74 (0.55–0.98)	0.04	Favorable	0.88(0.69–1.14)	0.66
BMP2	rs235756	Favorable	0.64 (0.37–1.10)	0.11	Favorable	0.72(0.53–0.99)	0.04
BMP4	rs8014071	Favorable	0.64 (0.44–0.93)	0.04	Favorable	0.76(0.52–1.14)	0.46
SMAD3	rs4776342	Favorable	0.71 (0.54–0.94)	0.02	Favorable	0.84(0.68–1.03)	0.09
SMAD3	rs1210217	Favorable	0.64 (0.47–0.86)	0.03	Favorable	0.81(0.62–1.05)	0.12
SMAD4	rs7244227	Favorable	0.66 (0.46–0.96)	0.03	Favorable	0.80(0.56–1.14)	0.91
SMAD4	rs12456284	Favorable	0.86 (0.59–1.25)	0.44	Favorable	0.77(0.6–0.99)	0.04
SMAD6	rs12913975	Favorable	0.61 (0.42–0.90)	0.01	Favorable	0.76(0.56–1.02)	0.29
BMP4	rs8014363	Unfavorable	1.61 (1.03–2.56)	0.04	Unfavorable	1.14(0.87–1.49)	0.60	Group 4
ACVR2A	rs1424954	Unfavorable	1.82 (0.93–3.45)	0.08	Unfavorable	1.72(1.03–2.86)	0.04
SMAD1	rs11939979	Unfavorable	1.33 (0.87–2.04)	0.89	Unfavorable	1.39(1.05–1.82)	0.02
SMAD1	rs2118438	Unfavorable	1.47 (0.53–4.17)	0.95	Unfavorable	1.33(1.03–1.75)	0.03
SMAD3	rs6494633	Unfavorable	1.43 (0.91–2.27)	0.12	Unfavorable	1.20(1.01–1.43)	0.04
SMAD3	rs11632964	Unfavorable	1.37 (0.94–1.96)	0.92	Unfavorable	1.52(1.05–2.17)	0.02
SMAD6	rs4776831	Unfavorable	1.16 (0.76–1.75)	0.95	Unfavorable	1.37(1.04–1.79)	0.02

^aAdjusted for age, sex, ethnicity, smoking status, clinical stage, PS and chemotherapy regimen. Results in bold are significant at P < 0.05.